The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies.
Serena Di Cosimo
No relevant relationships to disclose
Danila Serpico
No relevant relationships to disclose
Anna Tessari
No relevant relationships to disclose
Luca Porcu
No relevant relationships to disclose
Leonardo Molino
No relevant relationships to disclose
Valter Torri
No relevant relationships to disclose
Filippo G. De Braud
Consultant or Advisory Role - Novartis; SERVIER
Research Funding - GlaxoSmithKline; Novartis; Pierre Fabre Medicament; Roche